By Kevin Madagan
Ampersand Capital Partners has announced its acquisition of Nektar Therapeutics’ PEGylation reagent manufacturing business.
The business, which will be branded Gannet BioChem and continue to operate out of its facility in Huntsville, Alabama, develops, scales and manufactures polyethylene glycol (PEG) reagents, which are used in advanced biopharmaceutical and therapeutic products.